Consensus Edwards Lifesciences Corporation

Equities

EW

US28176E1082

Market Closed - Nyse Other stock markets 04:00:02 2023-12-06 pm EST			5-day change	1st Jan Change
69.49 ^USD	+0.93%		+3.06%	-6.86%

Dec. 06	Edwards Lifesciences Insider Sold Shares Worth $245,006, According to a Recent SEC Filing	MT
Dec. 04	Morgan Stanley Cuts Price Target on Edwards Lifesciences to $80 From $102, Maintains Overweight Rating	MT

Evolution of the average Target Price on Edwards Lifesciences Corporation

Price target over the last 5 years

History : Analyst Recommendations

fbc1f34030a44f6ac31430.FfpJTnifM05-6TNT1FDQTGukm8WI3dLkd3Yl-t_jURY.WLg7CTL5VCcpomQ9rX2bPh_tyJS7k7yhNBJMv4amA3xUuCY3T95UKzqecg~fd77cdb394cb098b8915f6b39d01aa21

Analyst Recommendations on Edwards Lifesciences Corporation

Morgan Stanley Cuts Price Target on Edwards Lifesciences to $80 From $102, Maintains Overweight Rating	Dec. 04	MT
RBC Trims Price Target on Edwards Lifesciences to $80 From $82 Ahead of Investor Day, Keeps Outperform Rating	Dec. 04	MT
ANALYST RECOMMENDATIONS : Adobe, Broadcom, Comcast, Fair Isaac, Salesforce...	Dec. 04
Wolfe Research Downgrades Edwards Lifesciences to Underperform From Peer Perform, Price Target is $57	Nov. 28	MT
ANALYST RECOMMENDATIONS : Boeing, Datadog, Estee Lauder, Qualcomm, Snowflake...	Nov. 28
Deutsche Bank Cuts Edwards Lifesciences Price Target to $64 From $90, Maintains Hold Rating	Oct. 27	MT
Citigroup Lowers Price Target on Edwards Lifesciences to $85 From $94, Maintains Buy Rating	Oct. 26	MT
TD Cowen Adjusts Edwards Lifesciences Price Target to $80 From $100, Maintains Outperform Rating	Oct. 26	MT
Wells Fargo Lowers Price Target on Edwards Lifesciences to $75 From $88, Maintains Equalweight Rating	Oct. 26	MT
RBC Cuts Price Target on Edwards Lifesciences to $82 From $86, Keeps Outperform Rating	Oct. 26	MT
ANALYST RECOMMENDATIONS : Adobe, Live Nation, Meta, Snap, Wpp...	Oct. 26
UBS Cuts Price Target on Edwards Lifesciences to $79 From $95, Keeps Neutral Rating	Oct. 16	MT
Citigroup Cuts Edwards Lifesciences' Price Target to $94 From $110, Keeps Buy Rating	Oct. 02	MT
ANALYST RECOMMENDATIONS : Amgen, Best Buy, Comcast, Fedex, Mosaic...	Oct. 02
Oppenheimer Upgrades Edwards Lifesciences to Outperform From Perform, $90 Price Target	Sep. 26	MT
Piper Sandler Adjusts Edwards Lifesciences' Price Target to $83 From $88, Keeps Neutral Rating	Sep. 08	MT
ANALYST RECOMMENDATIONS : Adobe, Alimentation Couche-Tard, Diageo, J&J, T-Mobile...	Sep. 08
Jefferies & Co Adjusts Edwards Lifesciences Price Target to $107 From $103, Maintains Buy Rating	Jul. 25	MT
Truist Securities Adjusts Price Target on Edwards Lifesciences to $105 From $101, Maintains Buy Rating	Jul. 19	MT
Baird Initiates Edwards Lifesciences With Outperform Rating, $107 Price Target	Jul. 19	MT
Citigroup Raises Price Target on Edwards Lifesciences to $110 From $101, Maintains Buy Rating	Jul. 11	MT
Truist Securities Increases Price Target on Edwards Lifesciences to $101 From $97, Maintains Buy Rating	May. 18	MT
Barclays Adjusts Price Target on Edwards Lifesciences to $102 From $94, Maintains Overweight Rating	Apr. 28	MT
Bernstein Raises Edwards Lifesciences' Price Target to $73 From $67, Maintains Underperform Rating	Apr. 27	MT
Piper Sandler Raises Edwards Lifesciences' Price Target to $83 From $80, Maintains Neutral Rating	Apr. 27	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

69.49USD

Average target price

79.36USD

Spread / Average Target

+14.20%

High Price Target

98USD

Spread / Highest target

+41.03%

Low Price Target

57USD

Spread / Lowest Target

-17.97%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Edwards Lifesciences Corporation

Morgan Stanley
RBC Capital Markets
Wolfe Research
Deutsche Bank Securities
Citigroup
TD Cowen
Wells Fargo Securities
UBS
Oppenheimer
Piper Sandler
Jefferies & Co.
Truist Securities
Baird
Barclays
Bernstein
Mizuho Securities
Stifel Nicolaus
Raymond James
Evercore ISI
Canaccord Genuity
Goldman Sachs
Cowen
SVB Leerink
BofA Securities
Credit Suisse
JPMorgan Chase
Atlantic Equities

Ratings for Edwards Lifesciences Corporation

Trading Rating :

Investor Rating :

ESG Refinitiv :

B+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar